Hemogenyx Pharmaceuticals Plc announced the appointment of Mr. Stuart Tinch as Director of Quality. Stuart brings over seven years of Good Manufacturing Practice ("GMP") expertise to Hemogenyx Pharmaceuticals. He will be instrumental in creating a culture and system of quality to ensure that the Company's therapies, such as HEMO-CAR-T, which is currently being prepared for clinical trials, are held to the standards of current GMP regulations.

Stuart's appointment takes the Company forward toward its first clinical clinical trials. Stuart joins Hemogenyx Pharmaceuticals from the manufacturing division of Expression Therapeutics INC ("Expression") where he was the Senior Manager of Viral Vector Manufacturing. There he worked to set up Expression's GMP facility and to assist in the design and implementation of its quality systems. Stuart previously worked at the Vector Production Facility ("VPF") at Cincinnati Children's Hospital Medical Center where he progressed to be Senior GxP Specialist and Supervisor of GMP manufacturing of viral vectors.

At the VPF he was involved in and supervised over 70 GMP manufacturing cycles both for academics and pharmaceutical companies. Stuart received his BS in Biochemistry from Miami University.